Subscribe
Share
Share
Embed
Ferrero launches a Fulfil DTC shop in Germany, a fiber trial cuts knee pain, grocers eye post-GLP-1 shoppers, and Holland & Barrett commits €17.5m to Ireland.
Ferrero is betting on owned e-commerce for Fulfil in Germany, and a clinical trial just gave gut-health brands a credible joint-health story. Two big commercial signals for supplement and functional food marketers today.
In this episode:
The Health Marketing Daily is a concise briefing for marketers and founders in supplements, functional food and consumer health, hosted by Marco & Klara. New episode every day.
Enjoying the show? A quick rating or review on Apple Podcasts or Spotify helps other marketers find us.
Also from Marco & Klara: The FMCG Marketing Daily · The Digital Commerce Daily
The daily briefing for professionals in health, nutrition, and wellness marketing. Every episode covers an ingredient of the day, the latest science and regulatory updates from EFSA and beyond, and the brand and market moves shaping the nutraceutical industry. Hosted by Klara and Marco — evidence-based, no hype, no bro-science. Built for formulators, brand managers, regulatory affairs teams, and anyone building in the health and nutrition space.
Marco: Four stories worth your attention today.
Klara: We're covering new clinical evidence linking fibre to joint health — which could reshape how gut-health brands talk to arthritis sufferers.
Marco: Then Ferrero goes direct-to-consumer in Germany with Fulfil.
Klara: We're looking at the post-GLP-1 opportunity for grocery retailers.
Marco: And Holland & Barrett drops €17.5 million on Irish expansion.
Klara: Let's get into it.
Marco: A new clinical trial suggests that a daily fibre supplement could reduce knee pain and improve muscle strength in people with osteoarthritis.
Marco: Fibre has always been the gut-health workhorse. You find it in functional foods, digestive supplements, and high-fibre snacks right across European retail. But the gut has never been its only story — researchers have increasingly been looking at how gut bacteria influence inflammation elsewhere in the body.
Marco: This trial, covered by Science Daily, found that participants taking a daily fibre supplement experienced significantly reduced knee osteoarthritis pain. They also showed measurable improvements in muscle strength and mobility. That second finding is the one that caught my attention. This isn't just about comfortable digestion — it's pointing toward fibre as a legitimate musculoskeletal ingredient.
Klara: The gut-joint connection is real science. We know that gut microbiome imbalance — when the bacteria in your digestive system are out of balance — can drive systemic inflammation. Inflammation is a core driver of osteoarthritis. So the biological mechanism is credible. What I need to see before getting too excited is the full methodology — sample size, control group design, duration, and the specific fibre type used. Not all fibres behave the same way in the gut.
Marco: Commercially, this is a significant opening. Active ageing is one of the fastest-growing segments in European health retail — think Boots, dm, and the pharmacy channel. A fibre supplement that carries a clinical story around joint pain hits multiple consumer motivations at once.
Klara: I'd hold on the joint health claims, though. EFSA — the EU's food safety authority — has strict rules on what you can actually say on pack. Clinical trials support the science. They don't automatically unlock authorised health claims in Europe.
Marco: Noted — and that's exactly the kind of nuance brands need to hear. Now let's move to our next story.
Klara: Ferrero Germany has launched a dedicated online shop for its Fulfil protein bar brand — a direct-to-consumer move that's worth paying attention to.
Klara: Fulfil sits at the crossroads of confectionery and sports nutrition. It's the kind of product that promises real protein content alongside genuine indulgence — think chocolate coating, dessert flavours, macro tracking. It's been growing steadily across European markets, including Germany, where it sits in dm, Rossmann, and the broader convenience channel.
Klara: The specific development here is that Ferrero Germany has built a standalone DTC online shop exclusively for Fulfil. Rather than relying entirely on retailer shelf space, they're now cultivating a direct relationship with the wellness consumer — owning the transaction, the data, and the brand experience end to end.
Marco: From a commercial standpoint, this is a loud signal. When a company with Ferrero's distribution muscle decides to invest in owned e-commerce for a functional sub-brand, they're not just adding a sales channel. They're saying the wellness shopper behaves differently and needs to be reached differently. Germany is a particularly interesting market for this — German consumers are often comparison-driven and research-heavy online before purchase. A DTC shop lets Fulfil tell its full nutritional story without competing for shelf space in a crowded snacking aisle.
Klara: My interest is in what happens to product claims in that DTC environment. On a retailer shelf, what you can say is tightly constrained — packaging space is limited, and retail buyers keep brands honest. A branded website gives you much more room to make nutritional arguments. That freedom is genuinely useful. It's also where brands start stretching beyond what the science actually supports.
Marco: That's a real tension — more storytelling space, more regulatory responsibility.
Klara: Precisely. Brands moving DTC need to bring their compliance thinking with them, not leave it at the warehouse door.
Marco: Up next, our third story of the day.
Marco: Grocery retailers are being asked to support a new wave of consumers who are coming off GLP-1 weight loss drugs — and the functional food and supplement opportunity is substantial.
Marco: GLP-1 drugs — injectable medications that suppress appetite and regulate blood sugar — have reshaped the weight management conversation globally. But a significant number of users are now discontinuing or stepping down their dosage. When people stop these drugs, hunger returns, muscle loss can accelerate, and maintaining results becomes genuinely difficult without nutritional support.
Marco: According to Grocery Dive, grocers are now being challenged to build dedicated strategies around this post-GLP-1 shopper. That means tailored product ranging, in-store education, and smarter placement across high-protein foods, appetite management supplements, gut health products, and nutrient-dense functional foods. The post-GLP-1 consumer isn't hypothetical anymore — they're walking the aisles today.
Marco: Commercially, this is a very specific, high-intent audience. These shoppers know what they've been through. They're motivated, they're research-literate, and they're actively looking for products that help them hold onto their results. For brands in protein, gut health, or satiety management, that's a rare combination.
Klara: The science here needs careful handling, though. Some of the categories likely to benefit — appetite management supplements in particular — have a patchy record on clinical evidence. EFSA-authorised appetite or satiety claims are narrow and hard-won. Brands rushing to position themselves as post-GLP-1 solutions need to make sure the evidence underneath those claims actually holds up.
Marco: That's the disagreement I'd expect from you — and it's a fair one to have. I think the retail momentum will move faster than the regulatory clarity on this. Brands that build credible, evidence-grounded propositions now will be far better positioned than those chasing the trend with weak claims.
Klara: The shopper deserves both the product and the proof. Not one without the other.
Marco: Let's move to our final story for today.
Klara: Holland & Barrett is putting €17.5 million into its Irish operations — and the implications stretch well beyond Ireland.
Klara: Holland & Barrett is one of the most powerful health retail chains in Europe. It shapes what supplements and wellness products millions of consumers can actually find and buy. When it commits serious capital to infrastructure, brands need to pay attention.
Klara: The investment covers both digital capabilities and physical retail fulfilment in Ireland — meaning faster delivery, better stock management, and a stronger omnichannel experience for Irish shoppers. The figure is €17.5 million, spread across the coming years. This follows a period in which Holland & Barrett has been positioning itself as a premium, award-recognised health retailer with clear European ambitions.
Marco: The commercial read here is straightforward. You don't spend €17.5 million on fulfilment infrastructure unless you're planning to move significantly more volume through it. Holland & Barrett is building the capacity to scale — and Ireland is likely a stepping stone in a broader European acceleration rather than an end destination in itself. Brands that aren't already in conversations about Irish ranging, or about H&B's wider EU strategy, are probably already behind where they need to be.
Klara: I'd frame this slightly differently. My concern is that rapid retail expansion can pull brands into rushed ranging decisions — getting onto H&B shelves is only valuable if your formulation, your labelling, and your health claims are fully compliant with EU regulations. Shelf space without compliance is a liability, not an asset.
Marco: That's a legitimate check. But standing on the sideline while a major retailer scales isn't the answer either. The brands that will win here are the ones that do both — solid compliance and commercial readiness — before Holland & Barrett comes looking for the next category fill.
Marco: Today's thread is clear — the brands that connect gut health, muscle function, and recovery nutrition to real clinical evidence are the ones retailers like Holland & Barrett will want on their shelves.
Klara: Just make sure that evidence actually holds up to EFSA scrutiny before it touches your packaging.